"Sumatriptan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
| Descriptor ID |
D018170
|
| MeSH Number(s) |
D02.065.884.750 D02.886.590.700.750 D03.633.100.473.914.907
|
| Concept/Terms |
Sumatriptan- Sumatriptan
- 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide
|
Below are MeSH descriptors whose meaning is more general than "Sumatriptan".
Below are MeSH descriptors whose meaning is more specific than "Sumatriptan".
This graph shows the total number of publications written about "Sumatriptan" by people in this website by year, and whether "Sumatriptan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 3 | 4 |
| 2003 | 2 | 2 | 4 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 3 | 5 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 4 | 0 | 4 |
| 2013 | 2 | 2 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sumatriptan" by people in Profiles.
-
Lipton RB, Dodick DW, Goadsby PJ, Burstein R, Adams AM, Lai J, Yu SY, Finnegan M, Kuang AW, Trugman JM. Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain. Neurology. 2022 10 25; 99(17):e1905-e1915.
-
Medrea I, Christie S, Tepper SJ, Thavorn K, Hutton B. Network meta-analysis of therapies for cluster headache: Effects of acute therapies for episodic and chronic cluster. Headache. 2022 04; 62(4):482-511.
-
Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, Dodick DW, Lipton RB. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018 May 24; 19(1):38.
-
Silberstein SD. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine. Expert Opin Drug Saf. 2018 Jan; 17(1):89-97.
-
Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J, Bigal M, Chichorro JG, Dodick D, Porreca F. Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia. 2017 May; 37(6):560-570.
-
Diener HC, Dodick DW. Headache research in 2015: progress in migraine treatment. Lancet Neurol. 2016 Jan; 15(1):4-5.
-
Green AL, Gu P, De Felice M, Dodick D, Ossipov MH, Porreca F. Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia. 2014 Jul; 34(8):594-604.
-
Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014 Feb; 34(2):114-25.
-
Tepper SJ. Clinical implications for breath-powered powder sumatriptan intranasal treatment. Headache. 2013 Sep; 53(8):1341-9.
-
Peterlin BL, Tietjen GE, Gower BA, Ward TN, Tepper SJ, White LW, Dash PD, Hammond ER, Haythornthwaite JA. Ictal adiponectin levels in episodic migraineurs: a randomized pilot trial. Headache. 2013 Mar; 53(3):474-90.